Physiologas for Home Hemodialysis Secures Funding from Toyota Boshoku Corporation
Key facts
- Physiologas for Home Hemodialysis Secures Funding from Toyota Boshoku Corporation
- Physiologas Technologies Inc. has successfully closed its Series A funding round, securing investment from Toyota Boshoku Corporation. The capital will be used to advance the development and testing of compact, safe home hemodialysis devices and related consumables. This initiative aims to improve the quality of life for end-stage renal disease patients in Japan by enabling more frequent and convenient treatment at home.
- Source: PR Times
- Date: April 1, 2026
Direct answer
Physiologas Technologies Inc. has successfully closed its Series A funding round, securing investment from Toyota Boshoku Corporation. The capital will be used to advance the development and testing of compact, safe home hemodialysis devices and related consumables. This initiative aims to improve the quality of life for end-stage renal disease patients in Japan by enabling more frequent and convenient treatment at home.
- Citation
- Physiologas for Home Hemodialysis Secures Funding from Toyota Boshoku Corporation (April 1, 2026), PR Times
- Source
- PR Times
- Date
- April 1, 2026
Physiologas Technologies Inc. has successfully closed its Series A funding round, securing investment from Toyota Boshoku Corporation. The capital will be used to advance the development and testing of compact, safe home hemodialysis devices and related consumables. This initiative aims to improve the quality of life for end-stage renal disease patients in Japan by enabling more frequent and convenient treatment at home.
📋 Article Processing Timeline
- 📰 Published: April 1, 2026 at 18:00
- 🔍 Collected: April 1, 2026 at 09:36
- 🤖 AI Analyzed: April 16, 2026 at 20:16 (370h 39m after Collected)
Physiologas Technologies Inc. (Headquarters: Sagamihara City, Kanagawa Prefecture; Representative Director: Kazuyoshi Miyawaki; hereinafter "the Company") is pleased to announce that it has completed the third close of its Series A round of financing by the end of March 2026.
In this round, a third-party allotment of new shares was conducted with Toyota Boshoku Corporation as the new subscriber.
The funds raised will be utilized for the design, development, prototyping, and non-clinical trials (electrical safety tests, electromagnetic compatibility tests, biological safety tests, etc.) of home hemodialysis devices and consumables.
Please refer to here for the press release by Toyota Boshoku Corporation.
About Home Hemodialysis:
Hemodialysis treatment at clinics is a time-consuming and physically demanding treatment for 340,000 end-stage renal disease patients in Japan, who typically receive it for 4 hours per session, three times a week. On the other hand, home hemodialysis treatment is known as a treatment method that improves patient QOL and has a good prognosis, as it eliminates the need for hospital visits and allows for frequent treatments.
However, in Japan, there are no dialysis devices developed specifically for home use. Therefore, patients must install large devices used in clinics, which require water supply and drainage piping, and complex operations such as water quality management and alarm response, in their homes. As a result, the number of patients is only around 800, and home hemodialysis is hardly widespread in Japan.
About Our Project:
Based on the research results of Kenichi Kokubo of Kitasato University (Associate Professor, Faculty of Medical and Health Sciences, Kitasato University, and CTO of the Company), the Company has commercialized a mechanism that recirculates dialysate within the device by adsorbing and removing uremic toxins, and is developing a compact and safe hemodialysis device exclusively for home use.
The introduction of our developed product is expected to lead to a high clinical prognosis, as it eliminates the need for hospital visits and enables frequent dialysis. Furthermore, as it improves the QOL of patients and their families, it is expected to have a social impact by promoting the return to society and employment of end-stage renal disease patients, and its high economic utility is anticipated.
About Physiologas Technologies Inc.:
Physiologas Technologies Inc. is a startup originating from Kitasato University, established in 2020 with the purpose of "innovating medicine with technology and delivering happier lives to patients and their families."
Inquiries regarding this matter:
Physiologas Technologies Inc. Public Relations
Inquiries: https://physiologas.co.jp/jp-contact.html
In this round, a third-party allotment of new shares was conducted with Toyota Boshoku Corporation as the new subscriber.
The funds raised will be utilized for the design, development, prototyping, and non-clinical trials (electrical safety tests, electromagnetic compatibility tests, biological safety tests, etc.) of home hemodialysis devices and consumables.
Please refer to here for the press release by Toyota Boshoku Corporation.
About Home Hemodialysis:
Hemodialysis treatment at clinics is a time-consuming and physically demanding treatment for 340,000 end-stage renal disease patients in Japan, who typically receive it for 4 hours per session, three times a week. On the other hand, home hemodialysis treatment is known as a treatment method that improves patient QOL and has a good prognosis, as it eliminates the need for hospital visits and allows for frequent treatments.
However, in Japan, there are no dialysis devices developed specifically for home use. Therefore, patients must install large devices used in clinics, which require water supply and drainage piping, and complex operations such as water quality management and alarm response, in their homes. As a result, the number of patients is only around 800, and home hemodialysis is hardly widespread in Japan.
About Our Project:
Based on the research results of Kenichi Kokubo of Kitasato University (Associate Professor, Faculty of Medical and Health Sciences, Kitasato University, and CTO of the Company), the Company has commercialized a mechanism that recirculates dialysate within the device by adsorbing and removing uremic toxins, and is developing a compact and safe hemodialysis device exclusively for home use.
The introduction of our developed product is expected to lead to a high clinical prognosis, as it eliminates the need for hospital visits and enables frequent dialysis. Furthermore, as it improves the QOL of patients and their families, it is expected to have a social impact by promoting the return to society and employment of end-stage renal disease patients, and its high economic utility is anticipated.
About Physiologas Technologies Inc.:
Physiologas Technologies Inc. is a startup originating from Kitasato University, established in 2020 with the purpose of "innovating medicine with technology and delivering happier lives to patients and their families."
Inquiries regarding this matter:
Physiologas Technologies Inc. Public Relations
Inquiries: https://physiologas.co.jp/jp-contact.html
FAQ
What is the significance of Toyota Boshoku Corporation's investment in Physiologas Technologies Inc. in 2024?
Toyota Boshoku Corporation's investment in Physiologas in 2024 supports the development of compact home hemodialysis devices for patients in Japan.
How will the Series A funding round benefit Physiologas Technologies Inc.'s product development?
The Series A funding will advance the development and testing of Physiologas's home hemodialysis devices and related consumables.
Which company provided funding to Physiologas Technologies Inc. for home hemodialysis innovation in 2024?
Toyota Boshoku Corporation provided funding to Physiologas Technologies Inc. for home hemodialysis innovation in 2024.
What type of medical device is Physiologas Technologies Inc. developing with Toyota Boshoku's support?
Physiologas is developing compact, safe home hemodialysis devices and consumables with support from Toyota Boshoku.
Why is Physiologas focusing on home hemodialysis solutions for end-stage renal disease patients in Japan?
Physiologas aims to improve the quality of life for end-stage renal disease patients in Japan through more frequent home treatments.